Suppr超能文献

患者对严重结节性痒疹的生活体验。

Patient Perspectives on Living With Severe Prurigo Nodularis.

机构信息

Evidera, Seattle, Washington.

Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland.

出版信息

JAMA Dermatol. 2023 Nov 1;159(11):1205-1212. doi: 10.1001/jamadermatol.2023.3251.

Abstract

IMPORTANCE

Because of a paucity of qualitative research on prurigo nodularis (PN), the symptoms and impacts of PN that are most important to patients are poorly understood.

OBJECTIVE

To explore patients' perspectives on their PN symptoms and to understand the impacts of the condition.

DESIGN, SETTING, AND PARTICIPANTS: One-on-one qualitative telephone interviews were held with English-speaking US adults aged 18 years or older with a confirmed diagnosis of PN, severe pruritus, and moderate to severe sleep disturbance. Participants were recruited via patient associations, patient panels, and social media posts. Interviews took place between September 10, 2020, and March 16, 2021.

MAIN OUTCOMES AND MEASURES

The main symptoms of PN and their impacts on quality of life were identified by content analysis of deidentified interview transcripts.

RESULTS

A total of 21 adults with PN (mean [SD] age, 53.1 [11.8] years; 15 [71%] female; 2 African American or Black patients [10%], 1 Asian patient [5%], and 18 White patients [86%]; of these, 1 patient [ 5%] had Hispanic or Latino ethnicity) participated in the interviews. All participants reported itch, pain associated with PN, bleeding or scabbing, and dry skin. Other frequently reported symptoms included lumps or bumps (95%), having a crust on the skin (95%), burning (90%), stinging (90%), lesions or sores (86%), skin discoloration (86%), and raw skin (81%). Of the 17 participants who indicated what their worst symptoms were, 15 (88%) identified itching as the worst or 1 of the worst symptoms. The most frequently reported impacts of PN for quality of life were changes in sleep (100%), daily life (100%), feelings or mood (95%), relationships (95%), social life (81%), and work or school (71%). Overall, the worst impact of PN was its association with impaired feelings or mood.

CONCLUSIONS AND RELEVANCE

This qualitative study suggests the importance of itching, sleep disturbance, and other symptoms and impacts of PN. This information can be used to guide end point selection in clinical trials and to inform patient-centric decision-making in clinical practice.

摘要

重要性

由于缺乏对结节性痒疹 (PN) 的定性研究,因此患者最关注的 PN 症状和影响仍知之甚少。

目的

探讨患者对 PN 症状的看法,并了解该疾病的影响。

设计、地点和参与者:2020 年 9 月 10 日至 2021 年 3 月 16 日期间,通过患者协会、患者小组和社交媒体帖子,对美国 18 岁及以上、确诊患有 PN、严重瘙痒和中重度睡眠障碍的英语使用者进行了一对一的定性电话访谈。

主要结果和措施

通过对匿名访谈记录进行内容分析,确定了 PN 的主要症状及其对生活质量的影响。

结果

共有 21 名 PN 患者(平均 [标准差] 年龄,53.1 [11.8] 岁;15 [71%] 为女性;2 名非裔美国人或黑人患者 [10%],1 名亚洲患者 [5%],18 名白人患者 [86%];其中,1 名患者 [5%]为西班牙裔或拉丁裔)参与了访谈。所有参与者均报告了瘙痒、与 PN 相关的疼痛、出血或结痂、皮肤干燥。其他常报告的症状包括肿块或隆起(95%)、皮肤有鳞屑(95%)、烧灼感(90%)、刺痛感(90%)、损伤或溃疡(86%)、皮肤变色(86%)和皮肤红肿(81%)。在 17 名报告了最严重症状的参与者中,15 名(88%)将瘙痒列为最严重或最严重症状之一。PN 对生活质量最常产生的影响是睡眠(100%)、日常生活(100%)、情绪或心情(95%)、人际关系(95%)、社交生活(81%)和工作或学业(71%)。总的来说,PN 最严重的影响是与情绪或心情受损有关。

结论和相关性

这项定性研究表明了瘙痒、睡眠障碍和其他 PN 症状和影响的重要性。这些信息可用于指导临床试验终点的选择,并为临床实践中以患者为中心的决策提供依据。

相似文献

1
Patient Perspectives on Living With Severe Prurigo Nodularis.
JAMA Dermatol. 2023 Nov 1;159(11):1205-1212. doi: 10.1001/jamadermatol.2023.3251.
2
Validation of the Peak Pruritus Numerical Rating Scale as a Patient-Reported Outcome Measure in Prurigo Nodularis.
Dermatol Ther (Heidelb). 2023 Oct;13(10):2403-2416. doi: 10.1007/s13555-023-00999-9. Epub 2023 Aug 24.
3
Worst Itch Numeric Rating Scale for Prurigo Nodularis: A Secondary Analysis of 2 Randomized Clinical Trials.
JAMA Dermatol. 2024 Aug 1;160(8):813-821. doi: 10.1001/jamadermatol.2024.1634.
4
The Sleep Disturbance Numerical Rating Scale: Content Validity, Psychometric Validation, and Meaningful Within-Patient Change in Prurigo Nodularis.
Dermatol Ther (Heidelb). 2023 Jul;13(7):1587-1602. doi: 10.1007/s13555-023-00962-8. Epub 2023 Jun 17.
8
A systematic review of interleukin-31 inhibitors in the treatment of prurigo nodularis.
Inflammopharmacology. 2024 Apr;32(2):991-1003. doi: 10.1007/s10787-024-01436-9. Epub 2024 Feb 8.
9
A critical review of dupilumab for adult patients with prurigo nodularis.
Expert Rev Clin Immunol. 2024 Mar;20(3):249-254. doi: 10.1080/1744666X.2023.2268291. Epub 2023 Oct 12.

引用本文的文献

1
Generalized prurigo nodularis after dermatomal herpes zoster: Resolution with nemolizumab.
JAAD Case Rep. 2025 Apr 14;60:122-125. doi: 10.1016/j.jdcr.2025.04.001. eCollection 2025 Jun.
3
Content Validity and Psychometric Validation of an Adapted Version of the Subject Sleep Diary in Prurigo Nodularis.
Dermatol Ther (Heidelb). 2025 Jun;15(6):1405-1426. doi: 10.1007/s13555-025-01406-1. Epub 2025 Apr 23.
5
A systematic review of interleukin-31 inhibitors in the treatment of prurigo nodularis.
Inflammopharmacology. 2024 Apr;32(2):991-1003. doi: 10.1007/s10787-024-01436-9. Epub 2024 Feb 8.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验